Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR)
May 14, 2026, 8:30 AM – 4:10 PM
UW Medicine at South Lake Union, Brotman Auditorium (D Bldg)
850 Republican St. Seattle 98109
Register here: https://diabetesmetabseminars.com/
Agenda
| 8:00–8:30 am | Light breakfast |
| 8:30–8:40 am | Salvatore Sechi, Ph.D., NIDDK/NIH History and purpose of TaMADOR |
| 8:40–8:50 am | Will Cefalu, M.D., NIDDK/NIH (Virtual) Welcome and Introduction |
| 8:50–9:30 am | Lori Sussel, Ph.D., University of Colorado Anschutz Medical Campus Paradoxically: Using proteomics to study non-coding RNAs |
| 9:30–9:55 am | Mike MacCoss, Ph.D., University of Washington School of Medicine Alterations in the plasma extracellular proteome due to treatment of type 1 diabetes |
| 9:55–10:20 am | Wei-Jun Qian, Ph.D., Pacific Northwest National Laboratory Single-islet proteomics maps pseudo-temporal Islet Immune responses and dysfunction in stage 1 T1D |
| 10:20–10:30 am | Coffee Break |
| 10:30–11:10 am | Joe Hedrick, Ph.D., C-PATH Institute Surrogate endpoint biomarkers for T1D interventions: a regulatory perspective |
| 11:10–11:35 am | Jessica Becker, MLS(ASCP), M.S., University of Washington School of Medicine Interlaboratory validation of an LC-MS/MS assay for glucagon and oxyntomodulin |
| 11:35–12:00 pm | Lorenz Nierves, Ph.D., Pacific Northwest National Laboratory MS-based simultaneous quantification of proinsulin and proglucagon processing products to investigate processing mechanisms |
| 12:00–12:45 pm | Lunch |
| 12:45–1:25 pm | Emily Sims, M.D., Indiana University School of Medicine Clinical Applications of Prohormone Ratios in Type 1 Diabetes |
| 1:25–1:50 pm | Andy Hoofnagle, MD PhD, University of Washington School of Medicine Quantification of proinsulin by proteolysis-aided-peptide immunoenrichment-LC-MS/MS |
| 1:50–2:15 pm | Jun Qu, Ph.D., University of Buffalo Cross-laboratory validation of a multiplexed LC-MS/MS assay for intact proinsulin, des-31,32/des-64,65 proinsulin, and C-peptide |
| 2:15–2:30 pm | Coffee Break |
| 2:30–2:55 pm | Wei-Jun Qian, Ph.D., Pacific Northwest National Laboratory Assessment of intact, des-31,32, and des-64,65 proinsulin as potential biomarkers in cross-sectional and longitudinal samples following T1D diagnosis |
| 2:55–3:20 pm | Sara Shijo, B.S., University of Washington School of Medicine Development of proglucagon assays |
| 3:20–4:00 pm | Steven Kahn, M.B., Ch.B., University of Washington School of Medicine (1) Beta-cell Peptides: It Does Not Stop With Insulin and C-peptide (2) Taking New Assays Into the "Real World": Working With the Diabetes Research Centers |
| 4:00–4:20 pm | Panel Discussion, C-peptide: Harmonization, clinical utility, and reimbursement requirements (Kuanysh Kabytaev, Des Schatz, Emily Sims, Andy Hoofnagle) |
